Narcolepsy Therapeutics Market Analysis and Forecast, 2022-2032 in BIS Research

  • Aug. 16, 2022, 8:47 a.m.
  • |
  • Public

The global narcolepsy therapeutics market is projected to reach $4,912.3 million by 2032 from $915.2 million in 2021 at a CAGR of 15.93% during the forecast period 2022-2032.
This The market is driven by certain factors, such as low satisfaction with available therapies, robust pipeline products, rising uptake of narcolepsy awareness programs, and improving diagnosis.

Recent Developments in the Global Narcolepsy Therapeutics Market

• On March 28, 2022, Jazz Pharmaceuticals PLC divested Sunosi. Axsome Therapeutics, Inc. will expand its presence in neuroscience by acquiring Sunosi (solriamfetol) from Jazz Pharmaceuticals PLC.
• On August 31, 2021, Health Canada approved Jazz Pharmaceutical’s Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy.
• On August 10, 2021, Harmony Biosciences LLC’s successful track record of Wakix motivated Blackstone to enter a strategic financing collaboration, where the company agreed to invest up to $330.0 million of financing and growth capital in Harmony Biosciences LLC.
• On September 16, 2021, Axsome Therapeutics, Inc. announced the enrolment of the first patient in the new phase 3 clinical trial SYMPHONY (a study evaluating a mechanistic approach to treating narcolepsy) of AXS-12 in narcoleptic patients.

No comments.

You must be logged in to comment. Please sign in or join Prosebox to leave a comment.